3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Interventions
pembrolizumab
21
Cisplatin
14
Carboplatin
13
Paclitaxel
12
Radiation
11
Radiotherapy
10
Doxorubicin
10
Nivolumab
9
Cyclophosphamide
9
Cytarabine
8
Vincristine
7
Radiotherapy, Intensity-Modulated
7
Metformin
7
Magnetic Resonance Spectroscopy
7
Injections
7
Etoposide
7
Leucovorin
6
Ipilimumab
6
Fluorouracil
6
Docetaxel
6
tislelizumab
5
Specimen Handling
5
Radiotherapy, Conformal
5
Radiosurgery
5
Prednisone
5
Pemetrexed
5
Methotrexate
5
Dexamethasone
5
Cetuximab
5
Bevacizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Cystectomy
×
30 days
×
Clear all
NCT03924856
2026-05-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3
Completed
907 enrolled